Anti-Inflammatory Effect Of Immp In A Metabolic Syndrome Model

The metabolic syndrome (MetS) is a prothrombotic, proinflammatory chronic state, that affects more than a third of the US and Mexican populations. The administration of IMMP (immunomodulator metallopeptide) in a model of liver damage modified markers of liver damage and decreases the degree of inflammation with decrement of IL‐6 levels. Therefore, the aim of this project was to evaluate the anti‐inflammatory effect of IMMP in a metabolic syndrome model. Zucker fa/fa and Zucker Lean rats were used to develop this protocol experimental. We formed 4 groups with 5 rats each: 1) Lean rats as control 2) Lean + IMMP 3) fa/fa rats as damage control and 4) fa/fa + IMMP. PBS was administered to the control groups and IMMP (50ng/Kg) to the treated group 3 times per week for 8 weeks. After of treatments were evaluated cytokine (IL‐6, TNF, IL‐1 β, IFN‐ γ and IL‐10), adipokines (leptin and adiponectin) and a chemokine (MCP‐1) in serum by ELISA and also were performed H&E histological staining in liver. The results showed a decrease inflammatory state with decreasing of levels of proinflammatory markers (IL‐6, TNF, IL‐1 β and IFN‐ γ, MCP‐1 and leptin) and increasing adiponectin levels in serum in fa/fa + IMMP group. In addition, we could see an improvement in the liver of fa/fa rats treated with the IMMP, decreasing the degree of steatosis in these rats. The IMMP had anti‐inflammatory effect and improved of damage liver in fa/fa rats.